Development and Validation of a Modified Khorana Score for Predicting Venous Thromboembolism in Newly Diagnosed Stage IV Lung Cancer.

IF 2.6 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Angiology Pub Date : 2025-03-01 Epub Date: 2023-11-04 DOI:10.1177/00033197231213197
Ya Qin, Xiao Liang, Hongshuai Wu, Xia Sun, Shuai Yan, Nanyao Wang, Ming Yuan, Qiong Wang, Dan Wu
{"title":"Development and Validation of a Modified Khorana Score for Predicting Venous Thromboembolism in Newly Diagnosed Stage IV Lung Cancer.","authors":"Ya Qin, Xiao Liang, Hongshuai Wu, Xia Sun, Shuai Yan, Nanyao Wang, Ming Yuan, Qiong Wang, Dan Wu","doi":"10.1177/00033197231213197","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to establish an effective model to identify metastatic lung cancer patients at high risk of venous thromboembolism (VTE). Patients diagnosed with stage IV lung cancer from January 2011 to June 2019 were included in the development cohort; those recruited from July 2019 to June 2021 were included in the validation cohort. Univariable and multivariable analyses determined the risk factors for VTE. Then we assessed the value for predicting VTE of the Khorana score and modified Khorana score in these two cohorts; 575 patients were included in the development cohort, and 202 patients in the validation cohort. Adenocarcinoma, D-dimer, and the Khorana score were independent risk factors for VTE. In the development cohort, the area under the receiver operating characteristic curve (AUC) of the Khorana score in patients with newly diagnosed stage IV lung cancer was 0.598 (95% CI, 0.512-0.684). The AUC of the modified Khorana score was 0.747 (95% CI, 0.689-0.805). The difference was statistically significant (<i>P</i> <.001). The AUC of the modified Khorana score in the validation cohort was 0.763 (95% CI, 0.661-0.865). The modified Khorana score is more able to accurately predict VTE in patients with newly diagnosed stage IV lung cancer than the Khorana score.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"264-270"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197231213197","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

We aimed to establish an effective model to identify metastatic lung cancer patients at high risk of venous thromboembolism (VTE). Patients diagnosed with stage IV lung cancer from January 2011 to June 2019 were included in the development cohort; those recruited from July 2019 to June 2021 were included in the validation cohort. Univariable and multivariable analyses determined the risk factors for VTE. Then we assessed the value for predicting VTE of the Khorana score and modified Khorana score in these two cohorts; 575 patients were included in the development cohort, and 202 patients in the validation cohort. Adenocarcinoma, D-dimer, and the Khorana score were independent risk factors for VTE. In the development cohort, the area under the receiver operating characteristic curve (AUC) of the Khorana score in patients with newly diagnosed stage IV lung cancer was 0.598 (95% CI, 0.512-0.684). The AUC of the modified Khorana score was 0.747 (95% CI, 0.689-0.805). The difference was statistically significant (P <.001). The AUC of the modified Khorana score in the validation cohort was 0.763 (95% CI, 0.661-0.865). The modified Khorana score is more able to accurately predict VTE in patients with newly diagnosed stage IV lung cancer than the Khorana score.

改良Khorana评分用于预测新诊断的癌症IV期静脉血栓栓塞的开发和验证。
我们的目的是建立一个有效的模型来识别转移性癌症患者静脉血栓栓塞(VTE)的高风险。将2011年1月至2019年6月诊断为癌症IV期的患者纳入发展队列;2019年7月至2021年6月招募的人员被纳入验证队列。单变量和多变量分析确定了VTE的危险因素。然后,我们评估了这两个队列中Khorana评分和修正的Khorana分数的VTE预测值;575名患者被纳入开发队列,202名患者被列入验证队列。腺癌、D-二聚体和Khorana评分是VTE的独立危险因素。在发展队列中,初诊IV期癌症患者Khorana评分的受试者操作特征曲线下面积(AUC)为0.598(95%CI,0.512-0.684),改良Khorana得分的AUC为0.747(95%CI),0.689-0.805,差异有统计学意义(P
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Angiology
Angiology 医学-外周血管病
CiteScore
5.50
自引率
14.30%
发文量
180
审稿时长
6-12 weeks
期刊介绍: A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信